Trevena, Inc. (TRVN) |
|
0.41 -0.003 (-0.63%)
|
06-29 18:41 |
|
Open: |
0.415 |
Pre. Close: |
0.4126 |
|
High:
|
0.4234 |
Low:
|
0.385 |
|
Volume:
|
920,757 |
Market Cap:
|
68(M) |
|
|
|
|
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.42 - 0.43 |
0.43 - 0.43 |
|
Low:
|
0.38 - 0.38 |
0.38 - 0.38 |
|
Close:
|
0.41 - 0.41 |
0.41 - 0.41 |
|
Technical analysis |
as of: 2022-06-29 4:58:08 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.57 One year: 0.66 |
| Support: |
Support1: 0.32  Support2: 0.22 |
| Resistance: |
Resistance1: 0.48 Resistance2: 0.57 |
| Pivot: |
0.42  |
| Moving Average: |
MA(5): 0.42 MA(20): 0.41
MA(100): 0.39 MA(250): 0.76 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 48.5 %D(3): 54.6 |
| RSI: |
RSI(14): 54 |
| 52-week: |
High: 1.64 Low: 0.18 |
| Average Vol(K): |
3-Month: 2,153 (K) 10-Days: 3,814 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRVN ] has closed above bottom band by 29.4%. Bollinger Bands are 43.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 28 Jun 2022
Is Trevena Inc (TRVN) a Smart Choice in Biotechnology Tuesday? - InvestorsObserver
Mon, 27 Jun 2022
Trevena to Present at the HC Wainwright Global Investment Conference - GuruFocus.com
Thu, 09 Jun 2022
Trevena, Inc. (NASDAQ:TRVN) to Post FY2023 Earnings of ($0.37) Per Share, Cantor Fitzgerald Forecasts - Defense World
Thu, 02 Jun 2022
Hot Penny Stocks Under $1 To Watch In June - Penny Stocks
Wed, 01 Jun 2022
Trevena (NASDAQ:TRVN) Upgraded at Zacks Investment Research - Defense World
Wed, 01 Jun 2022
Brokerages Expect Trevena, Inc. (NASDAQ:TRVN) Will Announce Quarterly Sales of $460000.00 - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
165 (M) |
|
% Held by Insiders
|
1.633e+008 (%) |
|
% Held by Institutions
|
1.3 (%) |
|
Shares Short
|
4,610 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.154e+007 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.37 |
|
EPS Est Next Year
|
-0.94 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-9 |
|
Return on Assets (ttm)
|
165.2 |
|
Return on Equity (ttm)
|
-31.3 |
|
Qtrly Rev. Growth
|
567000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-26.95 |
|
EBITDA (p.s.)
|
-170485 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-50 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
1.98 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
7.08e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
